News & Updates

Adalimumab concentrations negatively linked to inflammatory markers in RA
Adalimumab concentrations negatively linked to inflammatory markers in RA
22 Jul 2024

A negative association exists between adalimumab (ADA) concentrations and markers of inflammatory disease activity in rheumatoid arthritis (RA), including interleukin 6 (IL-6), reveals a study. Notably, ADA concentrations from 5 to 7 mg/L over the dose interval seem to contribute to better disease control.

Adalimumab concentrations negatively linked to inflammatory markers in RA
22 Jul 2024
High CRP level tied to earlier death in ILD
High CRP level tied to earlier death in ILD
21 Jul 2024
ALK+ NSCLC: Real-world patterns and outcomes of treatment after 1L brigatinib
ALK+ NSCLC: Real-world patterns and outcomes of treatment after 1L brigatinib
17 Jul 2024 byChristina Lau

Following first-line (1L) brigatinib treatment, most patients with ALK-positive (ALK+) non-small-cell lung cancer (NSCLC) received an ALK tyrosine kinase inhibitor (TKI) as second-line (2L) therapy and experienced prolonged clinical benefit, a retrospective chart review of patients enrolled in the phase III ALTA-1L trial has shown.

ALK+ NSCLC: Real-world patterns and outcomes of treatment after 1L brigatinib
17 Jul 2024